Medeon Biodesign (ROCO:6499) Debt-to-Equity : 0.10 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Medeon Biodesign Debt-to-Equity?

Medeon Biodesign's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$50.7 Mil. Medeon Biodesign's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$152.8 Mil. Medeon Biodesign's Total Stockholders Equity for the quarter that ended in Mar. 2024 was NT$2,133.5 Mil. Medeon Biodesign's debt to equity for the quarter that ended in Mar. 2024 was 0.10.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Medeon Biodesign's Debt-to-Equity or its related term are showing as below:

ROCO:6499' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.05 Max: 0.24
Current: 0.1

During the past 12 years, the highest Debt-to-Equity Ratio of Medeon Biodesign was 0.24. The lowest was 0.00. And the median was 0.05.

ROCO:6499's Debt-to-Equity is ranked better than
68.77% of 698 companies
in the Medical Devices & Instruments industry
Industry Median: 0.215 vs ROCO:6499: 0.10

Medeon Biodesign Debt-to-Equity Historical Data

The historical data trend for Medeon Biodesign's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medeon Biodesign Debt-to-Equity Chart

Medeon Biodesign Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.06

0.24

0.01

0.06

Medeon Biodesign Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.06	0.07	0.08	0.08	0.10

Competitive Comparison of Medeon Biodesign's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, Medeon Biodesign's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medeon Biodesign's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Medeon Biodesign's Debt-to-Equity falls into.

Medeon Biodesign Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Medeon Biodesign's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(36.686	+	162.224)	/	3597.442
	=	0.06

Medeon Biodesign's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(50.667	+	152.789)	/	2133.549
	=	0.10

Medeon Biodesign (ROCO:6499) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Medeon Biodesign Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Medeon Biodesign's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Medeon Biodesign (ROCO:6499) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medeon Biodesign Inc (ROCO:6499) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 116, HouGang Street, 7th Floor, Shilin District, Taipei, TWN, 11170

Website

http://www.medeonbio.com

Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.

Medeon Biodesign (ROCO:6499) Headlines

No Headlines